Phase II trial of Gemzar plus paraplatin [carboplatin] (plus Herceptin [trastuzumab] in HER2+ [human epidermal growth factor receptor-2 positive] patients) in metastatic breast cancer.

Trial Profile

Phase II trial of Gemzar plus paraplatin [carboplatin] (plus Herceptin [trastuzumab] in HER2+ [human epidermal growth factor receptor-2 positive] patients) in metastatic breast cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2010

At a glance

  • Drugs Carboplatin; Gemcitabine; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Dec 2009 Actual end date changed from Apr 2006 to Oct 2008 as reported by ClinicalTrials.gov.
    • 28 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top